Denali Therapeutics (NASDAQ:DNLI) Reaches New 1-Year High – Still a Buy?

Denali Therapeutics Inc. (NASDAQ:DNLI)’s stock price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $27.08 and last traded at $27.1010, with a volume of 114174 shares changing hands. The stock had previously closed at $26.69.

Analysts Set New Price Targets

Several brokerages have weighed in on DNLI. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Monday, April 20th. Stifel Nicolaus set a $41.00 price target on shares of Denali Therapeutics in a report on Monday, June 22nd. Wall Street Zen upgraded shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Deutsche Bank Aktiengesellschaft set a $31.00 price objective on shares of Denali Therapeutics in a report on Friday, May 22nd. Finally, The Goldman Sachs Group lifted their price objective on shares of Denali Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.25.

Denali Therapeutics Stock Up 0.4%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.28 and a current ratio of 9.28. The firm has a 50 day simple moving average of $21.51 and a two-hundred day simple moving average of $20.25. The stock has a market cap of $4.25 billion, a P/E ratio of -9.32 and a beta of 0.96.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same period in the prior year, the firm posted ($0.78) earnings per share. Equities research analysts predict that Denali Therapeutics Inc. will post -2.77 earnings per share for the current year.

Hedge Funds Weigh In On Denali Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNLI. Headlands Technologies LLC acquired a new position in Denali Therapeutics during the 2nd quarter valued at about $26,000. Johnson Financial Group Inc. acquired a new stake in shares of Denali Therapeutics in the 3rd quarter worth approximately $29,000. State of Wyoming acquired a new stake in shares of Denali Therapeutics in the 2nd quarter worth approximately $29,000. Fifth Third Bancorp bought a new position in shares of Denali Therapeutics in the first quarter valued at approximately $55,000. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Denali Therapeutics in the fourth quarter valued at approximately $57,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.